reddys q1 results, page-3

More trawling through Dr Reddys website has revealed another +ve comment on fondaparinux in the business highlights but no idea what the actual $ sales and profit margin for the last quarter were.

Business Highlights RECKONER
Q1FY14
Global Generics
Revenues from Global Generics segment at `21.9 billion recorded a YoY growth of 15%. Growth was primarily
driven by North America and Emerging market territories.
o Revenues from North America at `10.9 billion, recorded a YoY growth of 37%. Growth was primarily driven
by:
? Key difficult to synthesize products with limited competition launched during rest of the quarters of the
previous year i.e. montelukast granules, finasteride 1mg, isotretinoin, zoledronic acid (4mg/5mL),
metoprolol succinate extended release, etc.
? Two new products which have been launched during the quarter – zoledronic acid (5mg/100mL)
injection and lamotrigine XL.
? Significant traction in market share of products such as tacrolimus, fondaparinux, etc on a YoY basis.